Advertisement

Hepatitis B cure: From discovery to regulatory approval

Published:August 01, 2017DOI:https://doi.org/10.1016/j.jhep.2017.05.008

      Summary

      The majority of persons currently treated for chronic hepatitis B require long-term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardised appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials. To move the field forward and to expedite the pathway from discovery to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials aimed at hepatitis B cure. The consensus reached was that a complete sterilising cure, i.e., viral eradication from the host, is unlikely to be feasible. Instead, a functional cure characterised by sustained loss of hepatitis B surface antigen with or without hepatitis B surface antibody seroconversion, which is associated with improved clinical outcomes, in a higher proportion of patients than is currently achieved with existing treatments is a feasible goal. Development of standardised assays for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with development of novel antiviral and immune modulatory therapies such that approval of new treatments can be linked to the approval of new diagnostic assays used to measure efficacy or to predict response. Combination of antiviral and immune modulatory therapies will likely be needed to achieve functional hepatitis B virus cure. Limited proof-of-concept monotherapy studies to evaluate safety and antiviral activity should be conducted prior to proceeding to combination therapies. The safety of any new curative therapies will be paramount given the excellent safety of currently approved nucleos(t)ide analogues.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Liaw Y.F.
        • Sung J.J.
        • Chow W.C.
        • Farrell G.
        • Lee C.Z.
        • Yuen H.
        • et al.
        Lamivudine for patients with chronic hepatitis B and advanced liver disease.
        N Engl J Med. 2004; 351: 1521-1531
        • Bertoletti A.
        • Kennedy P.T.
        The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.
        Cell Mol Immunol. 2015; 12: 258-263
        • Kennedy P.T.
        • Sandalova E.
        • Jo J.
        • Gill U.
        • Ushiro-Lumb I.
        • Tan A.T.
        • et al.
        Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.
        Gastroenterology. 2012; 143: 637-645
        • Park J.J.
        • Wong D.K.
        • Wahed A.S.
        • Lee W.M.
        • Feld J.J.
        • Terrault N.
        • et al.
        Hepatitis B virus–specific and global T-cell dysfunction in chronic hepatitis B.
        Gastroenterology. 2016; 150: 684-695
        • Wu J.F.
        • Chiu Y.C.
        • Chang K.C.
        • Chen H.L.
        • Ni Y.H.
        • Hsu H.Y.
        • et al.
        Predictors of hepatitis B e antigen–negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.
        Hepatology. 2016; 63: 74-82
        • Liu J.
        • Yang H.I.
        • Lee M.H.
        • Jen C.L.
        • Batri-Utermann R.
        • Lu S.N.
        • et al.
        Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression.
        Hepatology. 2016; 64: 381-389
        • Tseng T.C.
        • Liu C.J.
        • Yang H.C.
        • Su T.H.
        • Wang C.C.
        • Chen C.L.
        • et al.
        High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
        Gastroenterology. 2012; 142 ([Quiz e13–e14]): 1140-1149
      1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
        J Hepatol. 2017; 67: 370-398
        • Kim G.A.
        • Lee H.C.
        • Kim M.J.
        • Ha Y.
        • Park E.J.
        • An J.
        • et al.
        Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
        J Hepatol. 2015; 62: 1092-1099
        • Yuen M.F.
        • Wong D.K.
        • Fung J.
        • Ip P.
        • But D.
        • Hung I.
        • et al.
        HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
        Gastroenterology. 2008; 135: 1192-1199
        • Gounder P.P.
        • Bulkow L.R.
        • Snowball M.
        • Negus S.
        • Spradling P.R.
        • Simons B.C.
        • et al.
        Nested case–control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
        Aliment Pharmacol Ther. 2016; 43: 1197-1207
        • Perrillo R.P.
        • Martin P.
        • Lok A.S.
        Preventing hepatitis B reactivation due to immunosuppressive drug treatments.
        JAMA. 2015; 313: 1617-1618
        • Chen C.J.
        • Yang H.I.
        • Su J.
        • Jen C.L.
        • You S.L.
        • Lu S.N.
        • et al.
        Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
        JAMA. 2006; 295: 65-73
        • Iloeje U.H.
        • Yang H.I.
        • Su J.
        • Jen C.L.
        • You S.L.
        • Chen C.J.
        • et al.
        Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
        Gastroenterology. 2006; 130: 678-686
        • Yang H.I.
        • Yuen M.F.
        • Chan H.L.
        • Han K.H.
        • Chen P.J.
        • Kim D.Y.
        • et al.
        Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.
        Lancet Oncol. 2011; 12: 568-574
        • Papatheodoridis G.
        • Dalekos G.
        • Sypsa V.
        • Yurdaydin C.
        • Buti M.
        • Goulis J.
        • et al.
        PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
        J Hepatol. 2016; 64: 800-806
        • Lee M.H.
        • Yang H.I.
        • Liu J.
        • Batria-Utermann R.
        • Jen C.L.
        • Iloeje U.H.
        • et al.
        Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
        Hepatology. 2013; 58: 546-554
        • Yuen M.F.
        • Tanaka Y.
        • Fong D.Y.
        • Fung J.
        • Wong D.K.
        • Yuen J.C.
        • et al.
        Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.
        J Hepatol. 2009; 50: 80-88
        • Yang H.I.
        • Sherman M.
        • Su J.
        • Chen P.J.
        • Liaw Y.F.
        • Iloeje U.H.
        • et al.
        Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
        J Clin Oncol. 2010; 28: 2437-2444
        • Jung K.S.
        • Kim S.U.
        • Ahn S.H.
        • Park Y.N.
        • Kim D.Y.
        • Park J.Y.
        • et al.
        Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).
        Hepatology. 2011; 53: 885-894
        • Masuzaki R.
        • Tateishi R.
        • Yoshida H.
        • Goto E.
        • Sato T.
        • Ohki T.
        • et al.
        Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.
        Hepatology. 2009; 49: 1954-1961
        • de Ledinghen V.
        • Vergniol J.
        • Barthe C.
        • Foucher J.
        • Chermak F.
        • Le Bail B.
        • et al.
        Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
        Aliment Pharmacol Ther. 2013; 37: 979-988
        • Kim S.U.
        • Lee J.H.
        • Kim D.Y.
        • Ahn S.H.
        • Jung K.S.
        • Choi E.H.
        • et al.
        Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.
        PLoS One. 2012; 7: e36676
        • Kim J.H.
        • Kim J.W.
        • Seo J.W.
        • Choe W.H.
        • Kwon S.Y.
        Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B.
        J Clin Gastroenterol. 2016; 50: 882-888
        • Terrault N.A.
        • Bzowej N.H.
        • Chang K.M.
        • Hwang J.P.
        • Jonas M.M.
        • Murad M.H.
        • et al.
        AASLD guidelines for treatment of chronic hepatitis B.
        Hepatology. 2016; 63: 261-283
        • Sarin S.K.
        • Kumar M.
        • Lau G.K.
        • Abbas Z.
        • Chan H.L.
        • Chen C.J.
        • et al.
        Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
        Hepatol Int. 2016; 10: 1-98
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: management of chronic hepatitis B virus infection.
        J Hepatol. 2012; 57: 167-185
        • Lok A.S.
        • Wu P.C.
        • Lai C.L.
        • Lau J.Y.
        • Leung E.K.
        • Wong L.S.
        • et al.
        A controlled trial of interferon with or without prednisone priming for chronic hepatitis B.
        Gastroenterology. 1992; 102: 2091-2097
        • Chan H.L.
        • Chan C.K.
        • Hui A.J.
        • Chan S.
        • Poordad F.
        • Chang T.T.
        • et al.
        Effects of tenofovir disoproxil fumarate in hepatitis B e antigen–positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
        Gastroenterology. 2014; 146: 1240-1248
        • Yapali S.
        • Talaat N.
        • Lok A.S.
        Management of hepatitis B: our practice and how it relates to the guidelines.
        Clin Gastroenterol Hepatol. 2014; 12: 16-26
        • Papatheodoridis G.
        • Vlachogiannakos I.
        • Cholongitas E.
        • Wursthorn K.
        • Thomadakis C.
        • Touloumi G.
        • et al.
        Discontinuation of oral antivirals in chronic hepatitis B: a systematic review.
        Hepatology. 2016; 63: 1481-1492
        • Marcellin P.
        • Ahn S.H.
        • Ma X.
        • Caruntu F.A.
        • Tak W.Y.
        • Elkashab M.
        • et al.
        Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B.
        Gastroenterology. 2016; 150: 134-144
        • Cheng H.R.
        • Kao J.H.
        • Wu H.L.
        • Tseng T.C.
        • Liu C.H.
        • Yang H.C.
        • et al.
        Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.
        Hepatol Int. 2015; 9: 35-42
        • Seto W.K.
        • Wong D.K.
        • Fung J.
        • Huang F.Y.
        • Lai C.L.
        • Yuen M.F.
        Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
        Hepatology. 2013; 58: 923-931
        • Lai C.L.
        • Yuen M.F.
        Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy.
        Hepatology. 2013; 57: 399-408
        • Marcellin P.
        • Gane E.
        • Buti M.
        • Afdhal N.
        • Sievert W.
        • Jacobson I.M.
        • et al.
        Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
        Lancet. 2013; 381: 468-475
        • Chang T.T.
        • Liaw Y.F.
        • Wu S.S.
        • Schiff E.
        • Han K.H.
        • Lai C.L.
        • et al.
        Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
        Hepatology. 2010; 52: 886-893
        • Blank A.
        • Markert C.
        • Hohmann N.
        • Carls A.
        • Mikus G.
        • Lehr T.
        • et al.
        First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.
        J Hepatol. 2016; 65: 483-489
        • Urban S.
        • Bartenschlager R.
        • Kubitz R.
        • Zoulim F.
        Strategies to inhibit entry of HBV and HDV into hepatocytes.
        Gastroenterology. 2014; 147: 48-64
        • Lucifora J.
        • Xia Y.
        • Reisinger F.
        • Zhang K.
        • Stadler D.
        • Cheng X.
        • et al.
        Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
        Science. 2014; 343: 1221-1228
        • Ely A.
        • Moyo B.
        • Arbuthnot P.
        Progress with developing use of gene editing to cure chronic infection with hepatitis B virus.
        Mol Ther. 2016; 24: 671-677
        • Seeger C.
        • Sohn J.A.
        Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA.
        Mol Ther. 2016; 24: 1258-1266
        • Tropberger P.
        • Mercier A.
        • Robinson M.
        • Zhong W.
        • Ganem D.E.
        • Holdorf M.
        Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation.
        Proc Natl Acad Sci USA. 2015; 112: E5715-E5724
        • Belloni L.
        • Allweiss L.
        • Guerrieri F.
        • Pediconi N.
        • Volz T.
        • Pollicino T.
        • et al.
        IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
        J Clin Invest. 2012; 122: 529-537
        • Decorsiere A.
        • Mueller H.
        • van Breugel P.C.
        • Abdul F.
        • Gerossier L.
        • Beran R.K.
        • et al.
        Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.
        Nature. 2016; 531: 386-389
        • Gish R.G.
        • Yuen M.F.
        • Chan H.L.
        • Given B.D.
        • Lai C.L.
        • Locarnini S.A.
        • et al.
        Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.
        Antiviral Res. 2015; 121: 97-108
        • Yuen M.-F.
        • Chan H.L.Y.
        • Liu K.
        • Given B.D.
        • Schluep T.
        • Hamilton J.
        • et al.
        Differential reductions in viral antigens expressed from cccDNA vs. integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520.
        J Hepatol. 2016; 64: 213
        • Klumpp K.
        • Lam A.M.
        • Lukacs C.
        • Vogel R.
        • Ren S.
        • Espiritu C.
        • et al.
        High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein.
        Proc Natl Acad Sci USA. 2015; 112: 15196-15201
        • Venkatakrishnan B.
        • Katen S.P.
        • Francis S.
        • Chirapu S.
        • Finn M.G.
        • Zlotnick A.
        Hepatitis B virus capsids have diverse structural responses to small-molecule ligands bound to the heteroaryldihydropyrimidine pocket.
        J Virol. 2016; 90: 3994-4004
        • Yuen M.-F.
        • Kim D.J.
        • Weilert F.
        • Chan H.L.-Y.
        • Lalezari J.
        • Hwang S.G.
        • et al.
        NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with peg-interferon (PegIFN), in treatment-naive HBeAg-positive patients: early reductions in HBV DNA and HBeAg.
        J Hepatol. 2016; 64: LB-∗∗∗06
        • Al-Mahtab M.
        • Bazinet M.
        • Vaillant A.
        Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection.
        PLoS One. 2016; 11: e0156667
        • Bazinet M.
        • Pantea V.
        • Placinta G.
        • Moscalu I.
        • Cebotarescu V.
        • Cojuhari L.
        • et al.
        Preliminary safety and efficacy of REP 2139-Mg or REP2165-Mg used in combination with tenofovir disoproxilfumarate and pegylated interferon alpha 2a in treatment naïve Caucasian patients with chronic HBeAg negative HBV infection.
        Hepatology. 2016; 64: LB-L7
        • Bertoletti A.
        • Ferrari C.
        Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.
        Gut. 2012; 61: 1754-1764
        • Tan A.
        • Koh S.
        • Bertoletti A.
        Immune response in hepatitis B virus infection.
        Cold Spring Harb Perspect Med. 2015; 5: a021428
        • Maini M.K.
        • Boni C.
        • Lee C.K.
        • Larrubia J.R.
        • Reignat S.
        • Ogg G.S.
        • et al.
        The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection.
        J Exp Med. 2000; 191: 1269-1280
        • Mason W.S.
        • Gill U.S.
        • Litwin S.
        • Zhou Y.
        • Peri S.
        • Pop O.
        • et al.
        HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant.
        Gastroenterology. 2016; 151: 986-998
        • Liu F.
        • Campagna M.
        • Qi Y.
        • Zhao X.
        • Guo F.
        • Xu C.
        • et al.
        Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes.
        PLoS Pathog. 2013; 9: e1003613
        • Lau D.T.
        • Everhart J.
        • Kleiner D.E.
        • Park Y.
        • Vergalla J.
        • Schmid P.
        • et al.
        Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
        Gastroenterology. 1997; 113: 1660-1667
        • Buster E.H.
        • Flink H.J.
        • Cakaloglu Y.
        • Simon K.
        • Trojan J.
        • Tabak F.
        • et al.
        Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2 b.
        Gastroenterology. 2008; 135: 459-467
        • Lanford R.E.
        • Guerra B.
        • Chavez D.
        • Giavedoni L.
        • Hodara V.L.
        • Brasky K.M.
        • et al.
        GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
        Gastroenterology. 2013; 144: 1508-1517
        • Menne S.
        • Tumas D.B.
        • Liu K.H.
        • Thampi L.
        • AlDeghaither D.
        • Baldwin B.H.
        • et al.
        Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B.
        J Hepatol. 2015; 62: 1237-1245
        • Gane E.J.
        • Lim Y.S.
        • Gordon S.C.
        • Visvanathan K.
        • Sicard E.
        • Fedorak R.N.
        • et al.
        The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
        J Hepatol. 2015; 63: 320-328
        • Janssen H.L.
        • Brunetto M.R.
        • Kim Y.J.
        • Ferrari C.
        • Massetto B.
        • Nguyen A.-H.
        • et al.
        Safety and efficacy of GS-9620 in virally-suppressed patients with chronic hepatitis B [Abstract].
        Hepatology. 2016; 64: 913 A-914 A
        • Guo F.
        • Han Y.
        • Zhao X.
        • Wang J.
        • Liu F.
        • Xu C.
        • et al.
        STING agonists induce an innate antiviral immune response against hepatitis B virus.
        Antimicrob Agents Chemother. 2015; 59: 1273-1281
        • Sato S.
        • Li K.
        • Kameyama T.
        • Hayashi T.
        • Ishida Y.
        • Murakami S.
        • et al.
        The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.
        Immunity. 2015; 42: 123-132
        • Korolowicz K.E.
        • Iyer R.P.
        • Czerwinski S.
        • Suresh M.
        • Yang J.
        • Padmanabhan S.
        • et al.
        Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B.
        PLoS One. 2016; 11: e0161313
        • Tzeng H.T.
        • Tsai H.F.
        • Liao H.J.
        • Lin Y.J.
        • Chen L.
        • Chen P.J.
        • et al.
        PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
        PLoS One. 2012; 7: e39179
        • Liu J.
        • Zhang E.
        • Ma Z.
        • Wu W.
        • Kosinska A.
        • Zhang X.
        • et al.
        Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.
        PLoS Pathog. 2014; 10: e1003856
        • Fisicaro P.
        • Valdatta C.
        • Massari M.
        • Loggi E.
        • Biasini E.
        • Sacchelli L.
        • et al.
        Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
        Gastroenterology. 2010; 138: 682-693
        • Johnson D.B.
        • Balko J.M.
        • Compton M.L.
        • Chalkias S.
        • Gorham J.
        • Xu Y.
        • et al.
        Fulminant myocarditis with combination immune checkpoint blockade.
        N Engl J Med. 2016; 375: 1749-1755
        • Gaggar A.
        • Coeshott C.
        • Apelian D.
        • Rodell T.
        • Armstrong B.R.
        • Shen G.
        • et al.
        Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study.
        Vaccine. 2014; 32: 4925-4931
        • Lok A.S.
        • Pan C.Q.
        • Han S.H.
        • Trinh H.N.
        • Fessel W.J.
        • Rodell T.
        • et al.
        Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.
        J Hepatol. 2016; 65: 509-516
        • Janssen H.L.
        • Yoon S.K.
        • Yoshida E.M.
        • Trinh H.N.
        • Rodell T.C.
        • Nguyen A.H.
        • et al.
        Safety and efficacy of GS-4774 in combination with TDF in patients with chronic hepatitis B [Abstract].
        Hepatology. 2016; 64: 122 A
        • Rehermann B.
        • Lau D.
        • Hoofnagle J.H.
        • Chisari F.V.
        Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.
        J Clin Invest. 1996; 97: 1655-1665
        • Boni C.
        • Laccabue D.
        • Lampertico P.
        • Giuberti T.
        • Vigano M.
        • Schivazappa S.
        • et al.
        Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
        Gastroenterology. 2012; 143: 963-973
        • Hong M.
        • Sandalova E.
        • Low D.
        • Gehring A.J.
        • Fieni S.
        • Amadei B.
        • et al.
        Trained immunity in newborn infants of HBV-infected mothers.
        Nat Commun. 2015; 6: 6588
        • Fattovich G.
        • Giustina G.
        • Realdi G.
        • Corrocher R.
        • Schalm S.W.
        Long-term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).
        Hepatology. 1997; 26: 1338-1342
        • Kim G.A.
        • Lim Y.S.
        • An J.
        • Lee D.
        • Shim J.H.
        • Kim K.M.
        • et al.
        HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
        Gut. 2014; 63: 1325-1332
        • Niederau C.
        • Heintges T.
        • Lange S.
        • Goldmann G.
        • Niederau C.M.
        • Mohr L.
        • et al.
        Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
        N Engl J Med. 1996; 334: 1422-1427
        • Thompson A.J.
        • Nguyen T.
        • Iser D.
        • Ayres A.
        • Jackson K.
        • Littlejohn M.
        • et al.
        Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
        Hepatology. 2010; 51: 1933-1944
        • Li W.
        • Zhao J.
        • Zou Z.
        • Liu Y.
        • Li B.
        • Sun Y.
        • et al.
        Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection.
        PLoS One. 2014; 9: e89046
        • Manesis E.K.
        • Papatheodoridis G.V.
        • Tiniakos D.G.
        • Hadziyannis E.S.
        • Agelopoulou O.P.
        • Syminelaki T.
        • et al.
        Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
        J Hepatol. 2011; 55: 61-68
        • van Bommel F.
        • Bartens A.
        • Mysickova A.
        • Hofmann J.
        • Kruger D.H.
        • Berg T.
        • et al.
        Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.
        Hepatology. 2015; 61: 66-76
        • Wang J.
        • Shen T.
        • Huang X.
        • Kumar G.R.
        • Chen X.
        • Zeng Z.
        • et al.
        Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
        J Hepatol. 2016; 65: 700-710
        • Jung K.S.
        • Park J.Y.
        • Chon Y.E.
        • Kim H.S.
        • Kang W.
        • Kim B.K.
        • et al.
        Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
        J Gastroenterol. 2016; 51: 830-839
        • Suzuki F.
        • Miyakoshi H.
        • Kobayashi M.
        • Kumada H.
        Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
        J Med Virol. 2009; 81: 27-33